Loading
A phase 1/2 trial of IDP-121 in multiple myeloma, diffuse large B-cell lymphoma, non-Hodgkin lymphoma and chronic lymphocytic leukaemia, run by IDP Discovery Pharma S.L., now recruiting.
A Phase 1/2 Study of IDP-121 in Patients With Relapsed/Refractory Hematologic Malignancies is a phase 1/2 interventional study registered as NCT05908409 by IDP Discovery Pharma S.L., with 37 participants planned, started 2023-06-05 and due to reach its primary completion in 2025-12-22. Interventions recorded: IDP-121.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Chronic lymphocytic leukaemia, Multiple myeloma, Diffuse large B-cell lymphoma, Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Diffuse large B-cell lymphoma, Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Diffuse large B-cell lymphoma, Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Multiple myeloma, Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Multiple myeloma, Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Chronic lymphocytic leukaemia, Diffuse large B-cell lymphoma, Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Chronic lymphocytic leukaemia, Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Multiple myeloma and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/